Compositions and methods for enhanced drug delivery
Patent 5607691 Issued on March 4, 1997. Estimated Expiration Date: May 24, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
424/449, Transdermal or percutaneous514/1, DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/26, Cyclopentanohydrophenanthrene ring system514/169, Cyclopentanohydrophenanthrene ring system DOAI514/183, Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI514/553, Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI514/556, Inner quaternary ammonium salt (e.g., betaine, etc.)604/20Infrared, visible light, ultraviolet, X-ray or electrical energy applied to body (e.g., iontophoresis, etc.)
The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.
Other References
Bodor, et al. Int. J. Pharm, 35(1-2) 47-59 1987 Improved Delivery Through Biological Membranes
Pratt et al., 1990, Principles of drug action: The basis of pharmacology 203-227 Principles of drug action: The basis of pharmacology
Russell-Jones et al., 1988, Proceed Intern. Symp. Control. Rel. Bioact. Mater. 85: 142-143 Vitamin B12: A novel carrier for orally presented antigens
Bodde et al., 1989, Biochemical Society 17 (3): 197-199 Transdermal peptide delivery
Sanderson et al., 1989, J. of Pharm. Sci. 78 (5): 361-364. Iontophoretic delivery of nonpeptide drugs: Formulation optimization for maximum skin permeability
Harris, Physical Medicine Library vol. IV, Therapeutic electricity and ultraviolet radiation, pp. 146-149
Foder et al., 1991, Science 251: 767-773 Light-Directed, spatially addressable parallel chemical synthesis
Bioworld 29 Jan 92, 3 (20): p. 1 FDA approves Elan's nicotine patch
Chien et al., 1989, J. Pharm. Sci. 78 (5): 376-383 Direct current iontophoretic transdermal delivery of peptide and protein drugs
Srinivasan et al., 1989, J. of Pharm. Sci. 78(5): 370-375 Transdermal iontophoretic drug delivery : Mechanistic analysis and application to polypeptide delivery
West, Textbook of Biochemistry, Ch. 6: 169-170 Lipids
Chien et al., 5 May 1989, J. Pharm. Sci. 78 (5): 353-354 Iontophoretic (transdermal) delivery of drugs: Overview of historical development
Fix et al., 1986, The American Physiological Society: G332-G340 Acylccarnitines: drug absorption-enhancing agents in the gastrointestinal tract
Banga et al., 1988, J. Controlled Release 7: 1-24 Iontophoretic delivery of drugs: Fundamentals, developments and biomedical applications
Behl et al., 1989, J. of Pharm. Sci. 78 (5): 355-360 Iontophoretic drug delivery: Effects of physicochemical factors on the skin uptake of nonpeptide drugs
Benet et al., Pharmacokinetics: The dynamics of drug absorption, Distributuion, and elimination. Ch. 1: 3-10 Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination
Phipps et al., 1989, J. of Pharm. Sci. 78 (5): 365-369 Iontophoretic delivery of model inorganic and drug ions
Ames et al., Feb. 1973, Proc. Natl. Acad. Sci. USA 70(2): 456-458 Illicit Transport: The Oligopeptide Permease
Bodor et al., 18 Sep. 1992, Science 257: 1698-1700 A strategy for delivering peptides into the central nervous system by sequential metabolism
Jacobson et al., 1986, Mol. Pharmacol. 29: 126-133 A fuctionalized congener approach to adenosine receptor antogonists: Amino Acid conjugates of 1,3-Dipropylxanthine
Jacobson et al., 1987, J. Med. Chem. 30: 1529-1532 Binary Drugs: Conjugates of purines and a peptide that binds to both adenosine and substance P receptor
May 24, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
